Some antipsychotics do reduce anxiety, particularly the newer “atypical” ones, but they are not a first-line treatment. Major clinical guidelines recommend standard antidepressants as the starting point for anxiety disorders, with antipsychotics reserved as a third-line option or an add-on when those initial treatments fall short. That said, the evidence for certain antipsychotics in specific anxiety conditions is real and worth understanding.
Why Atypical Antipsychotics Affect Anxiety
The older, “typical” antipsychotics like haloperidol mainly block dopamine receptors. That makes them effective for psychosis but largely unhelpful for anxiety on their own. Newer atypical antipsychotics work differently. They interact heavily with serotonin receptors, the same neurotransmitter system targeted by SSRIs and other common anxiety medications. Their influence on serotonin signaling, along with effects on adrenaline-related receptors, is what gives them the ability to dampen anxiety and stabilize mood in ways that older antipsychotics cannot.
This distinction matters. If your doctor prescribes an atypical antipsychotic for anxiety, they’re leveraging a genuinely different pharmacological profile, not just using a sedating drug to calm you down.
The Evidence for Generalized Anxiety
Quetiapine (Seroquel) has the strongest evidence base for generalized anxiety disorder. In a meta-analysis of randomized controlled trials, quetiapine produced anxiety score reductions significantly greater than placebo and comparable to SSRIs. Response rates were about 62% for quetiapine versus 60% for SSRIs in the studies reviewed. However, only the lower doses (50 mg and 150 mg per day) showed clear benefits over placebo for both response and remission. Those doses are far below what’s used for schizophrenia, where doses often reach 400 to 800 mg daily.
One practical number: for every eight or nine people treated with quetiapine for generalized anxiety, one additional person responds who would not have responded to placebo. That’s a modest but meaningful effect, roughly in line with what SSRIs deliver for the same condition.
When Anxiety Doesn’t Respond to Standard Treatment
The more common scenario for antipsychotics and anxiety isn’t standalone use. It’s augmentation, meaning adding an antipsychotic on top of an SSRI that isn’t doing enough on its own. Only 40% to 70% of people with anxiety-related conditions respond adequately to SSRIs alone, which leaves a large group looking for additional help.
The evidence is strongest in obsessive-compulsive disorder, where roughly one in three people who don’t respond to SSRIs will improve when an atypical antipsychotic is added. In one trial, 50% of patients who had failed SSRI treatment responded after risperidone was added, compared to none in the placebo group. Olanzapine augmentation showed similar results: 46% responded versus none on placebo. Aripiprazole has also shown consistent benefits across multiple controlled trials when added to an SSRI.
For social anxiety and panic disorder, the picture is murkier. Case reports suggest that olanzapine, quetiapine, and risperidone sometimes help with panic symptoms, but an equal number of reports describe these same drugs worsening those conditions. There are no large, reliable trials guiding their use for these specific disorders.
Where Antipsychotics Sit in Treatment Guidelines
Canadian treatment guidelines, among the most detailed on this topic, recommend antipsychotics only as a third-line option or add-on therapy for anxiety disorders. The first choice remains SSRIs or venlafaxine. Only one antipsychotic, trifluoperazine, has ever received FDA approval specifically for non-psychotic anxiety, and that was back in 2001. Everything else is off-label, meaning doctors prescribe it based on clinical judgment and available evidence rather than a formal regulatory approval for anxiety.
This doesn’t mean off-label use is inappropriate. It means the evidence hasn’t reached the threshold required for official approval, and that the risk-benefit calculation needs more careful consideration than it would for an SSRI.
Weight Gain and Metabolic Effects
Weight gain is the most common and practically disruptive side effect. In children and adolescents, up to 80% experience significant weight gain on antipsychotics. Adults fare somewhat better but are still at substantial risk. In studies without active management, around 79% of patients gained at least 7% of their body weight, a threshold considered clinically significant. With structured lifestyle interventions (diet, exercise monitoring), that number dropped to about 39%.
Antipsychotics also impair how your body handles blood sugar, raising the risk of metabolic problems over time. If you’re prescribed an antipsychotic for anxiety, expect your doctor to monitor your weight, blood sugar, and cholesterol regularly. The lower doses used for anxiety may reduce but do not eliminate these risks.
Tardive Dyskinesia and Movement Problems
Tardive dyskinesia, involuntary movements typically affecting the face, tongue, or jaw, is a well-known risk of antipsychotic use. The numbers are sobering: it develops in 20% to 50% of people taking antipsychotics overall. Atypical antipsychotics carry a lower risk (about 13%) than older typical ones (about 32%), but the risk is not zero even at low doses.
People taking low doses for conditions other than schizophrenia may actually develop these movement symptoms sooner than expected. Once tardive dyskinesia appears, it can persist even after the medication is stopped, though it sometimes improves gradually. This is one of the key reasons antipsychotics are not recommended as a first or second choice for anxiety.
Risks for Older Adults
Antipsychotic use in elderly patients carries a specific and serious warning. In 2005, the FDA issued a black-box warning after finding that atypical antipsychotics nearly doubled the risk of death in elderly people with dementia compared to placebo. Older typical antipsychotics turned out to be even riskier, with a 37% higher death rate than the atypical ones. These warnings apply regardless of the reason for prescribing, so an elderly person given a low-dose antipsychotic for anxiety faces this elevated risk.
Stopping Antipsychotics Safely
Antipsychotics should not be stopped abruptly. Withdrawal symptoms typically begin within four weeks of discontinuation and can last one to four weeks, sometimes longer for movement-related symptoms. Common withdrawal effects include nausea, headache, insomnia, restlessness, increased sweating, muscle pain, and, notably, a rebound increase in anxiety itself.
In one study comparing abrupt discontinuation to a gradual taper over about 11 months, the majority of people who stopped suddenly experienced withdrawal symptoms, while none of those who tapered slowly did. If you and your doctor decide to stop an antipsychotic, a slow, gradual reduction is essential. The lower your dose and the shorter your time on the medication, the easier this process tends to be, which is one advantage of the low doses typically used for anxiety.
The Bottom Line on Benefit vs. Risk
Atypical antipsychotics genuinely reduce anxiety in some people, with quetiapine at low doses performing comparably to SSRIs for generalized anxiety and several antipsychotics showing clear value as add-ons when SSRIs alone aren’t enough. But they come with side effects that SSRIs and other standard anxiety medications largely do not: meaningful weight gain, metabolic disruption, and a real risk of tardive dyskinesia that can outlast the treatment itself. For most people with anxiety, the standard medications deserve a thorough trial first. Antipsychotics make the most sense when those options have been genuinely exhausted, and when the severity of the anxiety justifies accepting a heavier side-effect profile.